News for INVENTIVA SA (US46124U1079.SG)

This format is in the process of being created from the filing. Please check back shortly. This is an excerpt of the original content. To continue reading it, access the... | February 9, 2021

The lockup period of Inventiva SA (IVA) ends on January 6. Daix, France-based Inventiva is a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases.

The lockup period of Inventiva SA (IVA) ends on January 6. Daix, France-based Inventiva is a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases.